Higher RTV doses of 200 mg BID and 400 mg BID co-administered with APV600 have resulted in no greater virologic suppression than 100 mg BID [ 25], and raising the dose of APV from 600 mg BID to 900 mg BID does not improve efficacy either, although it may increase the incidence of adverse events [ 20].
Studies 1 and 2 incorporated a forced titration from 20 mg BID to 60 mg BID.
If tolerability at 6 mg BID was confirmed, dose escalation to 8 mg BID and subsequently to 10 mg BID was allowed.
If tolerability at 6 mg BID was not confirmed, the subsequent dose was de-escalated to 4 mg BID.
Upon LTE study entry, patients from Phase 2 received 5 mg BID and patients from Phase 3 received 10 mg BID, with the exception of Chinese and Japanese patients in Phase 3 studies who received 5 mg BID.
Therefore, pregabaline (600 mg bid), clonazepam (6 mg tid), and gabapentine (800 mg bid) were tried in combination and with verapamil (360 mg bid).
Some, but unsatisfactory, clinical benefit was achieved with verapamil (360 mg bid), pregabaline (600 mg bid), and carbamazepine (1,400 mg bid).
The NNT for naratriptan 2.5 mg BID was not calculated.
He had a trial of sodium valproate (500 mg bid), amitryptiline (75 mg od), duloxetine (60 mg bid), naproxen (500 mg bid), ibuprofen (600 mg tds), and propranolol (60 mg bid).
The recommended asenapine starting dose is 10 mg bid with the option to reduce the dose to 5 mg bid if needed due to adverse effects/tolerability.
Patients with PSH were treated with gabapentin (300 mg bid), naproxen (275 mg bid), or amitriptyline (5 mg hs) based on the judgement of the specialist.
